Bio/Pharma News

Novavax Expands COVID-19 Collaboration and License Agreement with SK Bioscience

February 17, 2021

The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.

Novartis and the Bill & Melinda Gates Foundation Team Up to Develop Gene Therapy for Sickle Cell Disease

February 17, 2021

The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.

4D pharma Signs Clinical Trial Collaboration and Supply Agreement with Merck and Pfizer

February 15, 2021

4D pharma has signed a clinical trial collaboration and supply agreement with Merck and Pfizer for Bavencio (avelumab).

Exscientia Partners with University of Oxford on Alzheimer’s Treatments

February 12, 2021

Exscientia has formed a partnership with the ARUK-ODDI for the development of medicines targeting neuroinflammation to treat Alzheimer’s disease.

FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Lymphoma Treatment

February 10, 2021

The cell therapy will be manufactured for each individual patient at BMS’ immunotherapy manufacturing facility in Bothell, WA, and will be launched across a network of treatment centers.

AstraZeneca and IDT Biologika Plan Vaccine Capacity Expansion

February 10, 2021

The companies will build capacity in Germany that will be ready in 2022 and are exploring options for increasing volume in 2021.

AbbVie to Collaborate with Caribou Biosciences on CAR-T Cell Therapeutics

February 10, 2021

Through the agreement, AbbVie will use Caribou’s next-generation Cas12a CRISPR hybrid RNA–DNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies.

Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

February 04, 2021

The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.

Big Pharma Takes on Vaccine Production

February 03, 2021

As demand for COVID-19 vaccines increases, Big Pharma offers its manufacturing capacity and expertise.

J&J’s COVID-19 Vaccine Candidate Effective in Preventing Moderate to Severe COVID-19

January 29, 2021

The vaccine is 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination.